Stomach Ulcer
Conditions
Keywords
Rebamipide, gastric ulcer, healing rate, iatrogenic gastric ulcer after endoscopic submucosal dissection
Brief summary
Treatment strategy of post endoscopic submucosal dissection (ESD) ulcer is not yet conclusive. Rebamipide is a mucosal protective agent widely used in East Asia and has good effect on quality of ulcer healing (QOUH). The investigators will conduct this randomized controlled study to assess the effect of a combination therapy of rebamipide and proton pump inhibitor (PPI) on post ESD ulcer healing.
Interventions
DRUGRebamipide
Rebamipide 100mg Tid for 28days
DRUGpantoprazole
pantoprazole 40mg qd for 28days
Sponsors
Kangdong Sacred Heart Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients underwent ESD for gastric adenoma or cancer
Exclusion criteria
* subjects with previous gastric surgery * subjects taking aspirin, anticoagulant, or antiplatelet agent * subjects having malignancy except gastric cancer * pregnant or breast-feeding women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Healing efficacy of Rebamipide in the treatment of iatrogenic gastric ulcer | at 2month after endoscopic submucosal dissection (ESD) | Healing efficacy will be assessed by the change of ulcer size. Quality of Ulcer Healing(QOUH) wil be assessed by nodularity in the healed ulcer by two endoscopist. |
Countries
South Korea
Outcome results
None listed